-
Baekje Shenzhou Introduces Onsen Pharmaceuticals CDK2 Inhibitors for $1.33 billion
On November 21st, Baekje announced that it had reached a cooperation agreement with Ensem Therapeutics to introduce the CDK2 inhibitor ETX-197, which the latter is about to submit for IND (drug clini ... -
New indications for BeiGene PD-1 inhibitor for first-line treatment of hepatocellular carcinoma
On January 2, 2024, Baekje Shenzhou announced its PD-1 inhibitor Baekzeon& Reg; The new indication of (tirizizumab) has been approved by the National Medical Products Administration (NMPA) of China f ... -
MSD PD-1 inhibitor approved by the US FDA
On January 12th local time, Merck announced that the US Food and Drug Administration (FDA) has approved the use of Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemotherapy (C ... -
Mercado PD-1 inhibitor approved by the US FDA for the treatment of cervical cancer patients
On January 14th, Merck announced on January 12th local time that the US Food and Drug Administration (FDA) has approved Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemothera ... -
JAK1 inhibitor Xibico? New indications for age expansion approved in China
Southern Finance and Economics, March 4th - Today, Pfizer announced that it is a highly selective JAK1 inhibitor and an innovative oral small molecule targeted drug called Xibico; Reg; The new indica ... -
Merck PD-1 inhibitor CRDA approved as a new indication for melanoma treatment in China
On September 14th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA) has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment ...